For research use only. Not for therapeutic Use.
GSK1820795A, as a telmisartan analog, is a selective hGPR132a antagonist. GSK1820795A blocks activation of yeast cells expressing hGPR132a by N-acylamides[1]. GSK1820795A is also a angiotensin II antagonists and partial PPARγ agonists (compound 38)[2].
GSK1820795A blocks responses of yeast expressing hGPR132a to agonists NPGly, NLGly, linoleamide, and SB-583831[1].
| Catalog Number | I045624 |
| CAS Number | 2650253-86-2 |
| Synonyms | 5-(1-butylbenzimidazol-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]indazole |
| Molecular Formula | C35H34N8 |
| Purity | ≥95% |
| InChI | InChI=1S/C35H34N8/c1-3-5-21-42-32-13-9-8-12-31(32)36-35(42)26-18-19-30-29(23-26)33(43(39-30)20-4-2)22-24-14-16-25(17-15-24)27-10-6-7-11-28(27)34-37-40-41-38-34/h6-19,23H,3-5,20-22H2,1-2H3,(H,37,38,40,41) |
| InChIKey | XRXMDDDFTLKJHL-UHFFFAOYSA-N |
| SMILES | CCCCN1C2=CC=CC=C2N=C1C3=CC4=C(N(N=C4C=C3)CCC)CC5=CC=C(C=C5)C6=CC=CC=C6C7=NNN=N7 |
| Reference | [1]. Foster JR, et al. N-Palmitoylglycine and other N-acylamides activate the lipid receptor G2A/GPR132. Pharmacol Res Perspect. 2019;7(6):e00542. [2]. Lamotte Y, Faucher N, Sançon J, et al. Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists. Bioorg Med Chem Lett. 2014;24(4):1098-1103. |
